GLPGF Stock Price, Chart, Stats & News

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that pursues an acquisition-led strategy to build a pipeline of innovative medicines. Its lead program, gamgertamig (OM336), is a clinical-stage BCMAxCD3 T-cell engager obtained through its agreement to acquire Ouro Medicines, alongside preclinical programs and the internal candidate GLPG3667. The company is winding down its legacy cell therapy operations and maintains a strategic collaboration with Gilead Sciences.